Immune activity, vessel growth, metabolism
The verb boost supplies an answer before the clinical question has even been asked. These three compounds give it three different problems.
Claims beside trial findings
| Subject | Activity of interest | Finding that changes the claim |
|---|---|---|
| Thymosin alpha-1 | Immune-cell activity | The large phase 3 sepsis trial found no significant 28-day mortality benefit. |
| BPC-157 | Vessel growth and tissue repair | Angiogenesis experiments used chick membranes, rats and cultured cells; the human literature remains small. |
| Retatrutide | GIP, GLP-1 and glucagon receptor activation | The obesity trial measured substantial weight change alongside stomach symptoms and a heart-rate increase. |
A winner in that table would be an odd thing for me to declare. Each compound has a different proposed job, and the confidence belongs to a particular result.
Immune activity and survival
An improved immune marker made the earlier thymosin alpha-1 sepsis result biologically appealing. The later mortality trial disappointed that expectation. I object most strongly to the benefit already assumed by the word boost: even a plausible immune story has to survive a test of what happens to patients.
A blanket dismissal of every indication would trouble me for the opposite reason: it would overextend the trial. The thymosin alpha-1 page distinguishes the sepsis trials from the COVID-19 cohort and the oncology literature.
Repair and metabolic effects
BPC-157’s vessel-growth mechanism gives repair a concrete biological proposal. Its two-person intravenous safety pilot supplies very little clinical experience. I give BPC-157’s missing human recovery test more weight than its long list of proposed mechanisms.
Retatrutide has already reached much larger controlled human studies. Its weight result warrants enthusiasm, with pulse and tolerability included in the assessment. A general promise of metabolic improvement loses those distinctions.
The retatrutide and BPC-157 pages examine those separate cases. None of the three compounds has United States marketing approval, and the comparisons here offer no basis for a personal treatment choice.